Last reviewed · How we verify
CPA
CPA is a cancer immunotherapy vaccine that stimulates the immune system to recognize and attack cancer cells by presenting tumor-associated antigens.
CPA is a cancer immunotherapy vaccine that stimulates the immune system to recognize and attack cancer cells by presenting tumor-associated antigens. Used for Metastatic melanoma (in combination with checkpoint inhibitors), Non-small cell lung cancer (in development).
At a glance
| Generic name | CPA |
|---|---|
| Also known as | Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan |
| Sponsor | ImmunoVaccine Technologies, Inc. (IMV Inc.) |
| Drug class | Therapeutic cancer vaccine |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
CPA (also known as IMV Inc.'s therapeutic cancer vaccine) works by activating dendritic cells and T-cell responses against cancer antigens. It is designed to enhance the body's natural immune response to eliminate cancer cells, often used in combination with checkpoint inhibitors to improve anti-tumor immunity.
Approved indications
- Metastatic melanoma (in combination with checkpoint inhibitors)
- Non-small cell lung cancer (in development)
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Chills
Key clinical trials
- Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge
- A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 (PHASE1)
- The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans (NA)
- Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A (PHASE3)
- Practice-Based Evidence in Psychotherapy in Ecuador
- Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer (PHASE1)
- Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer (PHASE2)
- Compare Preperitoneal Analgesia to Epidural Analgesia for Pain Control After Colon and Rectal Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CPA CI brief — competitive landscape report
- CPA updates RSS · CI watch RSS
- ImmunoVaccine Technologies, Inc. (IMV Inc.) portfolio CI